- Home
- SNGX vs CWD Comparison
SNGX vs CWD Comparison
Compare SNGX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CWD
- Stock Information
- Founded
- SNGX 1987
- CWD 2009
- Country
- SNGX United States
- CWD United States
- Employees
- SNGX N/A
- CWD N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- SNGX Health Care
- CWD Finance
- Exchange
- SNGX Nasdaq
- CWD Nasdaq
- Market Cap
- SNGX 9.6M
- CWD 10.0M
- IPO Year
- SNGX 1987
- CWD 2023
- Fundamental
- Price
- SNGX $3.16
- CWD $0.50
- Analyst Decision
- SNGX
- CWD
- Analyst Count
- SNGX 0
- CWD 0
- Target Price
- SNGX N/A
- CWD N/A
- AVG Volume (30 Days)
- SNGX 46.1K
- CWD 70.9K
- Earning Date
- SNGX 11-08-2024
- CWD 11-12-2024
- Dividend Yield
- SNGX N/A
- CWD N/A
- EPS Growth
- SNGX N/A
- CWD N/A
- EPS
- SNGX N/A
- CWD N/A
- Revenue
- SNGX $364,183.00
- CWD $66,376,999.00
- Revenue This Year
- SNGX N/A
- CWD N/A
- Revenue Next Year
- SNGX $76.64
- CWD $38.91
- P/E Ratio
- SNGX N/A
- CWD N/A
- Revenue Growth
- SNGX N/A
- CWD N/A
- 52 Week Low
- SNGX $1.83
- CWD $0.37
- 52 Week High
- SNGX $19.20
- CWD $1.50
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- CWD 46.43
- Support Level
- SNGX $2.93
- CWD $0.44
- Resistance Level
- SNGX $3.35
- CWD $0.52
- Average True Range (ATR)
- SNGX 0.19
- CWD 0.03
- MACD
- SNGX -0.01
- CWD 0.01
- Stochastic Oscillator
- SNGX 37.10
- CWD 79.38
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.